FR04C0028I1 - - Google Patents
Info
- Publication number
- FR04C0028I1 FR04C0028I1 FR04C0028C FR04C0028I1 FR 04C0028 I1 FR04C0028 I1 FR 04C0028I1 FR 04C0028 C FR04C0028 C FR 04C0028C FR 04C0028 I1 FR04C0028 I1 FR 04C0028I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75720596A | 1996-11-27 | 1996-11-27 | |
PCT/US1997/019041 WO1998023761A1 (en) | 1996-11-27 | 1997-10-20 | HUMANIZED ANTI-CD11a ANTIBODIES |
Publications (2)
Publication Number | Publication Date |
---|---|
FR04C0028I1 true FR04C0028I1 (en) | 2005-02-11 |
FR04C0028I2 FR04C0028I2 (en) | 2007-10-26 |
Family
ID=25046834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR04C0028C Active FR04C0028I2 (en) | 1996-11-27 | 2004-12-10 |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP0941344B1 (en) |
JP (2) | JP3778945B2 (en) |
KR (1) | KR100532178B1 (en) |
AR (1) | AR008919A1 (en) |
AT (1) | ATE267257T1 (en) |
AU (1) | AU731817C (en) |
CA (1) | CA2272842C (en) |
DE (3) | DE69729209T2 (en) |
DK (2) | DK1516629T3 (en) |
ES (1) | ES2221045T3 (en) |
FR (1) | FR04C0028I2 (en) |
IL (3) | IL130143A0 (en) |
LU (1) | LU91122I2 (en) |
NL (1) | NL300163I2 (en) |
PT (1) | PT941344E (en) |
WO (1) | WO1998023761A1 (en) |
ZA (1) | ZA979599B (en) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
PT1135498E (en) | 1998-11-18 | 2008-04-30 | Genentech Inc | Antibody variants with higher binding affinity compared to parent antibodies |
SI1135498T1 (en) | 1998-11-18 | 2008-06-30 | Genentech Inc | Antibody variants with higher binding affinity compared to parent antibodies |
EP1854480A3 (en) * | 1999-03-19 | 2009-04-01 | Genentech, Inc. | Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist |
US6582698B1 (en) | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
CA2394862C (en) * | 1999-12-14 | 2011-10-11 | Genentech, Inc. | Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
US7560275B2 (en) | 1999-12-30 | 2009-07-14 | Vbi Technologies, L.L.C. | Compositions and methods for generating skin |
US7575921B2 (en) | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
WO2001051084A1 (en) * | 2000-01-14 | 2001-07-19 | Genentech, Inc. | Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 |
AU2001287000A1 (en) * | 2000-09-01 | 2002-03-13 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
WO2002057428A1 (en) | 2000-10-30 | 2002-07-25 | University Of Massachusetts | Isolation of spore-like cells from tissues exposed to extreme conditions |
WO2003066662A2 (en) | 2002-02-05 | 2003-08-14 | Genentech, Inc. | Protein purification |
US7323553B2 (en) | 2002-04-26 | 2008-01-29 | Genentech, Inc. | Non-affinity purification of proteins |
ES2357505T3 (en) | 2002-09-11 | 2011-04-27 | Genentech, Inc. | COMPOSITION AND NEW PROCEDURES FOR THE TREATMENT OF IMMUNORELATED DISEASES. |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
MXPA05011406A (en) * | 2003-04-23 | 2005-12-12 | Medarex Inc | Humanized antibodies to interferon alpha receptor-1 (ifnar-1). |
EP3095793B1 (en) | 2003-07-28 | 2020-03-25 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
CA2554965C (en) * | 2004-02-19 | 2015-08-11 | The Cbr Institute For Biomedical Research, Inc. | Antibodies specific for activated conformation of lfa-1 |
DE602005018325D1 (en) | 2004-02-19 | 2010-01-28 | Genentech Inc | ANTIBODIES WITH CORRECTED CDR |
US7396530B2 (en) | 2004-06-09 | 2008-07-08 | Genentech, Inc. | Method of treating granuloma annulare or sarcoid |
US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
FR2902799B1 (en) | 2006-06-27 | 2012-10-26 | Millipore Corp | METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
US8163886B2 (en) | 2006-12-21 | 2012-04-24 | Emd Millipore Corporation | Purification of proteins |
US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
ES2426158T3 (en) | 2007-01-22 | 2013-10-21 | Genentech, Inc. | Precipitation with polyelectrolyte and antibody purification |
JP5687057B2 (en) | 2007-07-09 | 2015-03-18 | ジェネンテック, インコーポレイテッド | Prevention of disulfide bond reduction during recombinant production of polypeptides. |
KR20140015166A (en) | 2007-10-30 | 2014-02-06 | 제넨테크, 인크. | Antibody purification by cation exchange chromatography |
CA3179151A1 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
WO2009151514A1 (en) | 2008-06-11 | 2009-12-17 | Millipore Corporation | Stirred tank bioreactor |
EP2145901B1 (en) | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Recombinant anti-MUC1 antibodies |
ES2749190T3 (en) | 2008-08-14 | 2020-03-19 | Genentech Inc | Methods to remove a contaminant using indigenous protein displacement ion exchange membrane chromatography |
MX2011002372A (en) | 2008-09-10 | 2011-04-04 | Genentech Inc | Compositions and methods for the prevention of oxidative degradation of proteins. |
US20110020327A1 (en) | 2008-12-16 | 2011-01-27 | Millipore Corporation | Purification of proteins |
EP2370561B1 (en) | 2008-12-16 | 2019-08-07 | EMD Millipore Corporation | Stirred tank reactor and method |
SG173812A1 (en) | 2009-02-27 | 2011-09-29 | Genentech Inc | Methods and compositions for protein labelling |
KR101822205B1 (en) | 2009-08-11 | 2018-01-25 | 제넨테크, 인크. | Production of proteins in glutamine-free cell culture media |
ES2787234T3 (en) | 2009-09-01 | 2020-10-15 | Hoffmann La Roche | Enhanced Protein Purification Through Modified Protein A Elution |
US8551775B2 (en) | 2009-11-12 | 2013-10-08 | Vbi Technologies, L.L.C. | Subpopulations of spore-like cells and uses thereof |
EP2531592A1 (en) | 2010-02-04 | 2012-12-12 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
MX354867B (en) | 2010-03-22 | 2018-03-23 | Genentech Inc Star | Compositions and methods useful for stabilizing protein-containing formulations. |
JP2013525484A (en) | 2010-05-03 | 2013-06-20 | ジェネンテック, インコーポレイテッド | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
ES2754210T3 (en) | 2010-05-17 | 2020-04-16 | Emd Millipore Corp | Stimulus-sensitive polymers for biomolecule purification |
KR20190067277A (en) | 2010-05-28 | 2019-06-14 | 제넨테크, 인크. | Decreasing lactate level and increasing polypeptide production by downregulating ldh and pdhk expression |
CA2802756C (en) | 2010-06-24 | 2021-05-04 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
EP2603525A1 (en) | 2010-08-13 | 2013-06-19 | F.Hoffmann-La Roche Ag | Antibodies to il-1beta and il-18, for treatment of disease |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
WO2012088272A1 (en) * | 2010-12-21 | 2012-06-28 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
AU2012355356B2 (en) | 2011-12-22 | 2017-10-12 | Genentech, Inc. | Ion exchange membrane chromatography |
SG10202007206WA (en) | 2012-03-27 | 2020-08-28 | Genentech Inc | Improved harvest operations for recombinant proteins |
EP3427721A1 (en) | 2012-05-18 | 2019-01-16 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
EP2934602B1 (en) | 2012-12-19 | 2019-02-27 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
EP3019523A4 (en) | 2013-07-09 | 2016-12-28 | Annexon Inc | Methods of treatment for alzheimer's disease and huntington's disease |
RU2019129525A (en) | 2013-07-16 | 2019-11-05 | Дженентек, Инк. | METHODS FOR TREATING CANCER USING ANTAGONISTS BINDING THE PD-1 AXIS AND TIGIT INHIBITORS |
SG11201700097WA (en) | 2014-07-09 | 2017-02-27 | Genentech Inc | Ph adjustment to improve thaw recovery of cell banks |
WO2016073685A1 (en) | 2014-11-05 | 2016-05-12 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
JP6861418B2 (en) | 2015-09-02 | 2021-04-28 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | Antibodies specific for human T cell immunoglobulin and ITIM domain (TIGIT) |
CR20180225A (en) | 2015-09-25 | 2018-07-09 | Genentech Inc | ANTI-TIGIT ANTIBODY AND METHODS OF USE |
US10723788B2 (en) | 2015-11-24 | 2020-07-28 | Annexon, Inc. | Anti-complement factor C1q Fab fragments and uses thereof |
EP3436610A1 (en) | 2016-03-29 | 2019-02-06 | Geltor, Inc. | Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1 |
MX2019007433A (en) | 2016-12-22 | 2019-08-16 | Genentech Inc | Methods and formulations for reducing reconstitution time of lyophilized polypeptides. |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
BR112020025623A2 (en) | 2018-07-03 | 2021-03-23 | Bristol-Myers Squibb Company | methods of producing recombinant proteins |
EP3864127A1 (en) | 2018-10-10 | 2021-08-18 | Boehringer Ingelheim International GmbH | Method for membrane gas transfer in high density bioreactor culture |
TW202102266A (en) | 2019-04-01 | 2021-01-16 | 美商建南德克公司 | Compositions and methods for stabilizing protein-containing formulations |
JP2022526434A (en) | 2019-04-12 | 2022-05-24 | ジェルター, インコーポレイテッド | Recombinant elastin and its production |
JP2022543781A (en) | 2019-08-01 | 2022-10-14 | ブリストル-マイヤーズ スクイブ カンパニー | Method for improving protein productivity in fed-batch cell culture |
KR20230073270A (en) | 2020-09-22 | 2023-05-25 | 브리스톨-마이어스 스큅 컴퍼니 | Methods of producing therapeutic proteins |
WO2023015234A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
WO2023049687A1 (en) | 2021-09-21 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ236792A (en) * | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
-
1997
- 1997-10-20 DK DK04004941.3T patent/DK1516629T3/en active
- 1997-10-20 DE DE69729209T patent/DE69729209T2/en not_active Expired - Lifetime
- 1997-10-20 IL IL13014397A patent/IL130143A0/en active IP Right Grant
- 1997-10-20 KR KR10-1999-7004671A patent/KR100532178B1/en not_active IP Right Cessation
- 1997-10-20 JP JP52464598A patent/JP3778945B2/en not_active Expired - Lifetime
- 1997-10-20 WO PCT/US1997/019041 patent/WO1998023761A1/en not_active Application Discontinuation
- 1997-10-20 PT PT97912841T patent/PT941344E/en unknown
- 1997-10-20 DE DE1997629209 patent/DE122004000047I2/en active Active
- 1997-10-20 DK DK97912841T patent/DK0941344T3/en active
- 1997-10-20 DE DE200412000047 patent/DE122004000047I1/en active Pending
- 1997-10-20 EP EP97912841A patent/EP0941344B1/en not_active Expired - Lifetime
- 1997-10-20 AU AU49929/97A patent/AU731817C/en not_active Expired
- 1997-10-20 ES ES97912841T patent/ES2221045T3/en not_active Expired - Lifetime
- 1997-10-20 EP EP04004941A patent/EP1516629B1/en not_active Expired - Lifetime
- 1997-10-20 CA CA2272842A patent/CA2272842C/en not_active Expired - Lifetime
- 1997-10-20 AT AT97912841T patent/ATE267257T1/en active
- 1997-10-27 ZA ZA979599A patent/ZA979599B/en unknown
- 1997-11-04 AR ARP970105146A patent/AR008919A1/en active IP Right Grant
-
1999
- 1999-05-26 IL IL130143A patent/IL130143A/en not_active IP Right Cessation
-
2004
- 2004-11-10 LU LU91122C patent/LU91122I2/en unknown
- 2004-11-12 NL NL300163C patent/NL300163I2/en unknown
- 2004-12-10 FR FR04C0028C patent/FR04C0028I2/fr active Active
-
2005
- 2005-08-02 JP JP2005224609A patent/JP4309383B2/en not_active Expired - Lifetime
-
2006
- 2006-05-11 IL IL175583A patent/IL175583A0/en not_active IP Right Cessation